<?xml version="1.0" encoding="UTF-8"?>
<p>This “ProTide” strategy has been successfully deployed in the synthesis of bioactive ribonucleoside analogues [
 <xref rid="B11-viruses-11-00365" ref-type="bibr">11</xref>,
 <xref rid="B12-viruses-11-00365" ref-type="bibr">12</xref>], including the Food and Drug Administration-(FDA) approved hepatitis C virus (HCV) drug, sofosbuvir [
 <xref rid="B13-viruses-11-00365" ref-type="bibr">13</xref>]. Sofosbuvir has recently been shown by multiple groups to also be active against ZIKV in vitro and in vivo [
 <xref rid="B14-viruses-11-00365" ref-type="bibr">14</xref>,
 <xref rid="B15-viruses-11-00365" ref-type="bibr">15</xref>,
 <xref rid="B16-viruses-11-00365" ref-type="bibr">16</xref>,
 <xref rid="B17-viruses-11-00365" ref-type="bibr">17</xref>], demonstrating that ribonucleoside analogue ProTides are an attractive avenue for the development of novel, selective antivirals against ZIKV.
</p>
